Literature DB >> 20631351

Liver x receptor signaling pathways and atherosclerosis.

Anna C Calkin1, Peter Tontonoz.   

Abstract

First discovered as orphan receptors, liver X receptors (LXRs) were subsequently identified as the nuclear receptor target of the cholesterol metabolites, oxysterols. There are 2 LXR receptors encoded by distinct genes: LXRalpha is most highly expressed in the liver, adipose, kidney, adrenal tissues, and macrophages and LXRbeta is ubiquitously expressed. Despite differential tissue distribution, these isoforms have 78% homology in their ligand-binding domain and appear to respond to the same endogenous ligands. Work over the past 10 years has shown that the LXR pathway regulates lipid metabolism and inflammation via both the induction and repression of target genes. Given the importance of cholesterol regulation and inflammation in the development of cardiovascular disease, it is not surprising that activation of the LXR pathway attenuates various mechanisms underlying atherosclerotic plaque development. In this brief review, we will discuss the impact of the LXR pathway on both cholesterol metabolism and atherosclerosis.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20631351      PMCID: PMC2919217          DOI: 10.1161/ATVBAHA.109.191197

Source DB:  PubMed          Journal:  Arterioscler Thromb Vasc Biol        ISSN: 1079-5642            Impact factor:   8.311


  44 in total

Review 1.  Atherosclerosis. the road ahead.

Authors:  C K Glass; J L Witztum
Journal:  Cell       Date:  2001-02-23       Impact factor: 41.582

2.  Cooperative NCoR/SMRT interactions establish a corepressor-based strategy for integration of inflammatory and anti-inflammatory signaling pathways.

Authors:  Serena Ghisletti; Wendy Huang; Kristen Jepsen; Chris Benner; Gary Hardiman; Michael G Rosenfeld; Christopher K Glass
Journal:  Genes Dev       Date:  2009-03-15       Impact factor: 11.361

3.  Oxidized LDL downregulates ATP-binding cassette transporter-1 in human vascular endothelial cells via inhibiting liver X receptor (LXR).

Authors:  Yi Zhu; Hailing Liao; Xuefen Xie; Yuan Yuan; Tzong-Shyuan Lee; Nanping Wang; Xian Wang; John Y-J Shyy; Michael B Stemerman
Journal:  Cardiovasc Res       Date:  2005-08-15       Impact factor: 10.787

4.  Macrophage apoptosis in advanced atherosclerosis.

Authors:  Ira Tabas; Tracie Seimon; Jenelle Timmins; Gang Li; Wahseng Lim
Journal:  Ann N Y Acad Sci       Date:  2009-09       Impact factor: 5.691

5.  LXR ligand lowers LDL cholesterol in primates, is lipid neutral in hamster, and reduces atherosclerosis in mouse.

Authors:  Elaine M Quinet; Michael D Basso; Anita R Halpern; David W Yates; Robert J Steffan; Valerie Clerin; Christine Resmini; James C Keith; Thomas J Berrodin; Irene Feingold; Wenyan Zhong; Helen B Hartman; Mark J Evans; Stephen J Gardell; Elizabeth DiBlasio-Smith; William M Mounts; Edward R LaVallie; Jay Wrobel; Ponnal Nambi; George P Vlasuk
Journal:  J Lipid Res       Date:  2009-03-24       Impact factor: 5.922

6.  Crosstalk between LXR and toll-like receptor signaling mediates bacterial and viral antagonism of cholesterol metabolism.

Authors:  Antonio Castrillo; Sean B Joseph; Sagar A Vaidya; Margaret Haberland; Alan M Fogelman; Genhong Cheng; Peter Tontonoz
Journal:  Mol Cell       Date:  2003-10       Impact factor: 17.970

7.  Accumulation of foam cells in liver X receptor-deficient mice.

Authors:  Gertrud U Schuster; Paolo Parini; Ling Wang; Siegfried Alberti; Knut R Steffensen; Göran K Hansson; Bo Angelin; Jan-Ake Gustafsson
Journal:  Circulation       Date:  2002-08-27       Impact factor: 29.690

8.  LXR-activating oxysterols induce the expression of inflammatory markers in endothelial cells through LXR-independent mechanisms.

Authors:  Fulvio Morello; Elisa Saglio; Alessio Noghero; Domenica Schiavone; Tracy Ann Williams; Andrea Verhovez; Federico Bussolino; Franco Veglio; Paolo Mulatero
Journal:  Atherosclerosis       Date:  2009-04-11       Impact factor: 5.162

9.  TLR/MyD88 and liver X receptor alpha signaling pathways reciprocally control Chlamydia pneumoniae-induced acceleration of atherosclerosis.

Authors:  Yoshikazu Naiki; Rosalinda Sorrentino; Michelle H Wong; Kathrin S Michelsen; Kenichi Shimada; Shuang Chen; Atilla Yilmaz; Anatoly Slepenkin; Nicolas W J Schröder; Timothy R Crother; Yonca Bulut; Terence M Doherty; Michelle Bradley; Zory Shaposhnik; Ellena M Peterson; Peter Tontonoz; Prediman K Shah; Moshe Arditi
Journal:  J Immunol       Date:  2008-11-15       Impact factor: 5.422

10.  Liver X receptor activator downregulates angiotensin II type 1 receptor expression through dephosphorylation of Sp1.

Authors:  Ikuyo Imayama; Toshihiro Ichiki; Dan Patton; Keita Inanaga; Ryohei Miyazaki; Hideki Ohtsubo; Qingping Tian; Kotaro Yano; Kenji Sunagawa
Journal:  Hypertension       Date:  2008-04-28       Impact factor: 10.190

View more
  111 in total

Review 1.  Crosstalk between reverse cholesterol transport and innate immunity.

Authors:  Kathleen M Azzam; Michael B Fessler
Journal:  Trends Endocrinol Metab       Date:  2012-03-10       Impact factor: 12.015

2.  Nanoparticles containing a liver X receptor agonist inhibit inflammation and atherosclerosis.

Authors:  Xue-Qing Zhang; Orli Even-Or; Xiaoyang Xu; Mariska van Rosmalen; Lucas Lim; Suresh Gadde; Omid C Farokhzad; Edward A Fisher
Journal:  Adv Healthc Mater       Date:  2014-08-22       Impact factor: 9.933

Review 3.  Emerging roles for nuclear receptors in the pathogenesis of age-related macular degeneration.

Authors:  Goldis Malek; Eleonora M Lad
Journal:  Cell Mol Life Sci       Date:  2014-08-26       Impact factor: 9.261

Review 4.  Liver x receptors in atherosclerosis and inflammation.

Authors:  Seung-Soon Im; Timothy F Osborne
Journal:  Circ Res       Date:  2011-04-15       Impact factor: 17.367

5.  LXRα regulates macrophage arginase 1 through PU.1 and interferon regulatory factor 8.

Authors:  Benoit Pourcet; Jonathan E Feig; Yuliya Vengrenyuk; Adrian J Hobbs; Diane Kepka-Lenhart; Michael J Garabedian; Sidney M Morris; Edward A Fisher; Inés Pineda-Torra
Journal:  Circ Res       Date:  2011-07-14       Impact factor: 17.367

Review 6.  Nuclear receptors as therapeutic targets for Alzheimer's disease.

Authors:  Shweta Mandrekar-Colucci; Gary E Landreth
Journal:  Expert Opin Ther Targets       Date:  2011-07-01       Impact factor: 6.902

Review 7.  Genetics of HDL-C: a causal link to atherosclerosis?

Authors:  Julian C van Capelleveen; Andrea E Bochem; M Mahdi Motazacker; G Kees Hovingh; John J P Kastelein
Journal:  Curr Atheroscler Rep       Date:  2013-06       Impact factor: 5.113

Review 8.  Detection and treatment of atherosclerosis using nanoparticles.

Authors:  Jia Zhang; Yujiao Zu; Chathurika S Dhanasekara; Jun Li; Dayong Wu; Zhaoyang Fan; Shu Wang
Journal:  Wiley Interdiscip Rev Nanomed Nanobiotechnol       Date:  2016-05-31

Review 9.  Animal models of atherosclerosis.

Authors:  Godfrey S Getz; Catherine A Reardon
Journal:  Arterioscler Thromb Vasc Biol       Date:  2012-03-01       Impact factor: 8.311

Review 10.  Liver X receptors in lipid signalling and membrane homeostasis.

Authors:  Bo Wang; Peter Tontonoz
Journal:  Nat Rev Endocrinol       Date:  2018-08       Impact factor: 43.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.